Hep E vax provides 4 years of protection; Zimbabwe to launch HIV jab trial;

> Novavax ($NVAX) has appointed Brian Rosen as its VP of government affairs. Release

> Targovax is expanding expand an ongoing Phase I/II study of its cancer vaccine candidate. Release

> Scientists in Zimbabwe are preparing to launch the country's first-ever HIV vaccine trial. More

> A vaccine against hepatitis E provided protection against the virus for more than 4 years, researchers say. Report

And Finally... H7N9 bird flu has the makings of a pandemic virus, scientists caution. More

Suggested Articles

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.

Since the FDA released new COVID-19 vaccine guidance, HHS Secretary Alex Azar has discussed firing FDA Commissioner Stephen Hahn, Politico reports.